Patents by Inventor Rama K. Narla

Rama K. Narla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Cancer with TOR Kinase Inhibitors
    Publication number: 20230338370
    Abstract: Provided herein are methods for treating or preventing triple negative breast cancer or hormone receptor positive breast cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having triple negative breast cancer or hormone receptor positive breast cancer.
    Type: Application
    Filed: October 28, 2022
    Publication date: October 26, 2023
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla
  • ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20220280505
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Application
    Filed: November 8, 2021
    Publication date: September 8, 2022
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20220273650
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: October 7, 2021
    Publication date: September 1, 2022
    Inventors: Shuichan XU, Kristen Mae HEGE, Antonia LOPEZ-GIRONA, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 11166950
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20200253964
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
  • ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190282567
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Application
    Filed: June 3, 2019
    Publication date: September 19, 2019
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
  • Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
    Patent number: 10391092
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 27, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Toshiya Tsuji, Rama K. Narla, Kristen Mae Hege
  • ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190008852
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Application
    Filed: July 9, 2018
    Publication date: January 10, 2019
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20180235960
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 23, 2018
    Inventors: Shuichan XU, Kristen Mae HEGE, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY
    Publication number: 20180185361
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 5, 2018
    Inventors: HEATHER RAYMON, TOSHIYA TSUJI, RAMA K. NARLA, KRISTEN MAE HEGE
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9937170
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 10, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
    Patent number: 9937169
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 10, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Heather Raymon, Toshiya Tsuji, Rama K. Narla, Kristen Mae Hege
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9795607
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 24, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
    Publication number: 20170027932
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Application
    Filed: September 27, 2016
    Publication date: February 2, 2017
    Inventors: Shuichan XU, Kristen Mae HEGE, Antonia LOPEZ-GIRONA, Heather RAYMON, Rama K. NARLA, Rajesh CHOPRA
  • Treatment of cancer with TOR kinase inhibitors
    Patent number: 9493466
    Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 15, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Shuichan Xu, Kristen Mae Hege, Antonia Lopez-Girona, Heather Raymon, Rama K. Narla, Rajesh Chopra
  • SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    Publication number: 20160324861
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9428509
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: August 30, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 9346812
    Abstract: Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R1, R2, R3, and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: May 24, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Andrew Antony Calabrese, Brandon Jeffy, Dale Robinson, Dan Zhu, Dehua Huang, Jan Elsner, John Boylan, Lida Tehrani, Mark A. Nagy, Raj Kumar Raheja, Paul Erdman, Rama K. Narla, Roy L. Harris, Tam Minh Tran, Jennifer Riggs, Yuhong Ning, Shuichan Xu
  • PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
    Publication number: 20160024101
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Application
    Filed: October 5, 2015
    Publication date: January 28, 2016
    Inventors: Jan ELSNER, Kimberly Elizabeth FULTZ, Roy L. HARRIS, Branden Gingsee LEE, Loui MADAKAMUTIL, Deborah MORTENSEN, Rama K. NARLA, Garrick K. PACKARD, Patrick PAPA, Jason PARNES, Sophie PERRIN-NINKOVIC, Jennifer RIGGS, Sabita SANKAR, John SAPIENZA, Graziella I. SHEVLIN, Lida TEHRANI, Weiming XU, Jingjing ZHAO
  • METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY
    Publication number: 20140315900
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 23, 2014
    Applicant: Signal Pharmaceuticals, LLC
    Inventors: HEATHER RAYMON, TOSHIYA TSUJI, RAMA K. NARLA, KRISTEN MAE HEGE